ANI Pharmaceuticals Reports 29.6% Revenue Growth Driven by Rare Disease Expansion

TLDR

• Fourth-quarter revenue climbed 29.6% year-over-year to $247.1M.
• Cortrophin Gel generated $111.4M in Q4, expanding across multiple specialties.
• ILUVIEN contributed $19.8M with enhanced coverage and market penetration.
• Generics division expanded 28.2% to $100.8M driven by new product rollouts.
• Full-year 2026 revenue guidance set between $1.06B and $1.12B with adjusted EBITDA up to $290M.

Shares of ANI Pharmaceuticals (ANIP) demonstrated notable strength following a robust fourth-quarter performance that showcased accelerated revenue and profitability across multiple business lines. Trading closed at $77.15 before advancing to $78.68 in early pre-market activity. The pharmaceutical company achieved record annual sales while solidifying its foothold in rare disease therapeutics.

ANI Pharmaceuticals, Inc., ANIP

Rare Disease Division Powers Quarterly Revenue Acceleration

The rare disease business unit generated $131.3 million during the quarter, representing a year-over-year increase of 50.8%. Cortrophin Gel accounted for the majority of this growth with quarterly net sales of $111.4 million. ILUVIEN contributed an additional $19.8 million, bolstering the segment’s overall commercial momentum.

Demand for Cortrophin Gel remained robust as physicians across neurology, rheumatology, nephrology, and ophthalmology increasingly prescribed the therapy. Utilization for acute gouty arthritis flares grew significantly and now comprises over 15% of total prescriptions. Management plans to expand the rare disease commercial team by mid-2026 to capitalize on emerging market opportunities.

ILUVIEN’s performance benefited from enhanced reimbursement coverage and focused commercial execution. Targeted investments improved patient access pathways and drove higher adoption rates across approved uses. The company anticipates sustained momentum as distribution channels continue developing.

Generics Division Delivers Growth Through Strategic Product Launches

Quarterly generics revenue totaled $100.8 million, marking a 28.2% increase compared to the same period last year. A partnership-based product launch initiated in Q3 contributed substantially to the division’s performance. Several additional generics introduced throughout 2025 further enhanced revenue growth.

Royalty income within the segment declined due to reduced contributions from specific service arrangements. Nevertheless, the generics platform demonstrated operational resilience and consistent execution. The company maintains a disciplined approach to rolling out new generic formulations.

Brand product revenue decreased to $12.3 million as demand for certain offerings returned to normalized levels. This reduction reflected anticipated trends following previous quarters of elevated purchasing activity. Management continues prioritizing stable operations within the brand portfolio.

Financial Performance Reflects Margin Expansion and Profitability Growth

Total revenue for the quarter reached $247.1 million, a 29.6% increase from the prior-year period. GAAP gross margin improved primarily due to the elimination of purchase accounting adjustments that impacted earlier periods. Non-GAAP gross margin experienced slight compression as the product mix shifted toward higher royalty-bearing items.

Operating expenses rose in response to increased headcount and investments in rare disease and ophthalmology commercial infrastructure. Research and development spending declined modestly due to timing considerations related to active development programs. The company maintained strategic investments in initiatives designed to fuel long-term expansion.

Net income for the quarter totaled $27.5 million, representing a significant improvement from the prior year’s loss. Adjusted diluted earnings per share increased to $2.33, driven by revenue growth and operational efficiency gains. Adjusted EBITDA climbed to $65.4 million, a 30.6% year-over-year increase.

2026 Financial Outlook Supports Long-Term Growth Strategy

Management reaffirmed its 2026 revenue guidance, projecting total sales between $1.055 billion and $1.115 billion. Cortrophin Gel is forecast to deliver up to $575 million as commercial teams expand into additional specialty and primary care settings. ILUVIEN revenue is expected to reach as much as $83 million.

The company projects adjusted EBITDA will climb to $290 million, underscoring ongoing margin expansion. Earnings per share guidance points to further profitability improvements as operational leverage increases. ANI concluded 2025 with solid liquidity and generated $185.2 million in operating cash flow for the year.

The organization is focused on establishing itself as a prominent rare disease pharmaceutical company while continuing disciplined execution across its generics and brand segments.

The post ANI Pharmaceuticals Reports 29.6% Revenue Growth Driven by Rare Disease Expansion appeared first on Blockonomi.